Mosaic HIV-1 Vaccination Induces Anti-viral CD8⁺ T Cell Functionality in the Phase I/IIa Clinical Trial APPROACH

Investigators tested ex vivo viral inhibitory activity of T cell responses induced by a multivalent HIV vaccine based on the replication-incompetent recombinant adenovirus serotype 26 vectors with a mosaic immunogen strategy, designed for broad immune coverage of diverse HIV-1 strains.